Cyteir Therapeutics, Inc.
NASDAQ:CYT
Overview | Financials
Company Name | Cyteir Therapeutics, Inc. |
Symbol | CYT |
Currency | USD |
Price | 3.02 |
Market Cap | 108,714,262 |
Dividend Yield | 0% |
52-week-range | 1.65 - 3.19 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Markus F. Renschler M.D. |
Website | https://cyteir.com |
An error occurred while fetching data.
About Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the next-generation of precision oncology medicines. Its lead product CYT-0851, a novel, oral, once-daily, small molecule drug candidate that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD